Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.18
vs -0.30
Q2.23
N/A
-0.36
vs -0.15
Q3.23
N/A
-0.24
vs -0.14
Q4.23
N/A
-0.42
vs -0.09
Q1.24
N/A
-0.54
vs -0.18
Q2.24
N/A
-0.37
vs -0.36
Q3.24
N/A
-0.37
vs -0.24
Q4.24
N/A
-0.46
vs -0.42
Q1.25
N/A
-0.40
vs -0.54
Q2.25
N/A
-0.42
vs -0.37
Sales Growth
YoY
Current
Estimates
Q1.23
+29%
4.5M vs 3.5M
Q2.23
+22%
4.8M vs 3.9M
Q3.23
+16%
3.7M vs 3.2M
Q4.23
-15%
4.5M vs 5.4M
Q1.24
-34%
3M vs 4.5M
Q2.24
-24%
3.7M vs 4.8M
Q3.24
+21%
4.4M vs 3.7M
Q4.24
-36%
2.9M vs 4.5M
Q1.25
+10%
3.3M vs 3M
Q2.25
+31%
4.8M vs 3.7M
Return on Equity
QoQ
Q1.23
+4%
0.04
vs 0.02
Q2.23
+6%
0.06
vs 0.04
Q3.23
-33%
-0.33
vs 0.06
Q4.23
-58%
-0.58
vs -0.33
Q1.24
-47%
-0.47
vs -0.58
Q2.24
-45%
-0.45
vs -0.47
Q3.24
-21%
-0.21
vs -0.45
Q4.24
-50%
-0.50
vs -0.21
Institutionnal Ownership
QoQ
Q1.23
97
97
vs 96
1%
Q2.23
110
110
vs 97
13%
Q3.23
114
114
vs 110
4%
Q4.23
135
135
vs 114
18%
Q1.24
157
157
vs 135
16%
Q2.24
154
154
vs 157
-2%
Q3.24
168
168
vs 154
9%
Q4.24
180
180
vs 168
7%
globenewswire.com
6 hours ago
zacks.com
8 hours ago
globenewswire.com
8 hours ago
zacks.com
10 hours ago
seekingalpha.com
16 hours ago
globenewswire.com
17 hours ago
Forecast
1395%2025-Revenue
-221%2025-EPS
-30%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
35.00(128.01%)
Number of analyst
2
Last analyst upgrade/downgrade
Raymond James
upgradePrevious: Outperform
2024-08-19
Now: Strong Buy
Raymond James
initialisePrevious: Not converted
2024-08-16
Now: Outperform
Oppenheimer
initialisePrevious: Not converted
2024-06-24
Now: Perform
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
NASDAQ
Unprofitable
Unprofitable
-0.18Â ( -1.16%)
Relative Strenght
86
Volume Buzz
15%
Earning Acce
No
Dist 52w H.
9%Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics